Thoroughbred Financial Services LLC Purchases 246 Shares of Natera, Inc. (NASDAQ:NTRA)

Thoroughbred Financial Services LLC lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,031 shares of the medical research company’s stock after purchasing an additional 246 shares during the period. Thoroughbred Financial Services LLC’s holdings in Natera were worth $2,062,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. raised its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after acquiring an additional 332 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NTRA shares. Morgan Stanley boosted their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Robert W. Baird increased their target price on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Piper Sandler lifted their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Sanford C. Bernstein upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $178.12.

Natera Stock Down 3.5 %

Shares of NASDAQ NTRA opened at $133.87 on Friday. The company’s 50 day moving average price is $156.81 and its 200-day moving average price is $151.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a market capitalization of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 25,931 shares of Natera stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the completion of the sale, the chief financial officer now directly owns 109,665 shares of the company’s stock, valued at approximately $18,091,435.05. This trade represents a 19.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 325,922 shares of company stock worth $51,603,664 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.